Onartuzumab for Gastroesophageal Adenocarcinoma

Special Reports, Gastrointestinal Cancers (Issue 4), Volume 4, Issue 1

Manish A Shah, MD, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma.

Manish A Shah, MD, director of gastrointestinal oncology at Weill Cornell Medical College/New York Presbyterian Hospital, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma (GEC).

Clinical Pearls:

  • The MET pathway is often overexpressed in gastric cancer. If there is a MET amplification in addition to the overexpression, the cancer can be more aggressive.
  • The study found that the addition of onartuzumab to FOLFOX did not improve progression-free survival or overall survival in either an unselected population or in MET-positive patients.
  • More research is needed to identify patients that benefit from MET inhibition